SCHEMBL2993804

SCHEMBL2993804

COCCNC(=O)c1ccc(Cl)c(NC2=NC(=O)C(=Cc3ccc4ncccc4c3)S2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
HPGD P15428 1/20 0.41
DYRK3 O43781 3/20 0.40
AURKA O14965 1/20 0.40
AURKB Q96GD4 1/20 0.40
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MAPK1 P28482 1/20 0.40
CYP3A4 P08684 1/20 0.39
BRAF P15056 2/20 0.39
CISD1 Q9NZ45 1/20 0.38
PIK3CD O00329 1/20 0.38
PIM1 P11309 1/20 0.38
CSNK2A2 P19784 1/20 0.38
PIK3CA P42336 1/20 0.38
PIK3CG P48736 1/20 0.38
CLK1 P49759 1/20 0.38
CLK3 P49761 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2993800 1.00 HDAC1 (0.42) HDAC1HDAC6HPGDDYRK3AURKA
Trifluoroacetic Acid SCHEMBL4089208 0.95 HDAC1 (0.39) HDAC1HDAC6HPGDDYRK3AURKA
Trifluoroacetic Acid SCHEMBL4089216 0.95 HDAC1 (0.39) HDAC1HDAC6HPGDDYRK3AURKA
SCHEMBL2996295 0.92 HDAC1 (0.44) HDAC1HDAC6HPGDDYRK3AURKA
SCHEMBL2996301 0.92 HDAC1 (0.44) HDAC1HDAC6HPGDDYRK3AURKA
SCHEMBL2990908 0.91 HDAC1 (0.44) HDAC1HDAC6HPGDDYRK3AURKA
SCHEMBL2990906 0.91 HDAC1 (0.44) HDAC1HDAC6HPGDDYRK3AURKA
SCHEMBL2997101 0.91 DYRK3 (0.42) HDAC1HDAC6DYRK3AURKAAURKB
SCHEMBL2997096 0.91 DYRK3 (0.42) HDAC1HDAC6DYRK3AURKAAURKB
SCHEMBL2983859 0.90 HDAC1 (0.43) HDAC1HDAC6DYRK3AURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203692-A1 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION 2009-08-13 US claimed
EP-1885362-A2 NOVEL CHEMICAL COMPOUNDS Smithkline Beecham Corporation (US) 2008-02-13 EP claimed
WO-2006127458-A2 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-11-30 WO claimed
US-20100184774-A1 METHODS OF TREATMENT SMITHKLINE BEECHAM CORPORATION 2010-07-22 US disclosed
EP-2164494-A1 METHODS OF TREATMENT GlaxoSmithKline LLC (US) 2010-03-24 EP disclosed
US-20090203692-A1 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION 2009-08-13 US disclosed
WO-2008150837-A1 METHODS OF TREATMENT SMITHKLINE BEECHAM CORPORATION (US) 2008-12-11 WO disclosed
EP-1885362-A2 NOVEL CHEMICAL COMPOUNDS Smithkline Beecham Corporation (US) 2008-02-13 EP disclosed
WO-2006127458-A2 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184774-A1 METHODS OF TREATMENT OPRL1, BRCA1, PKD1 HDAC1 467/4885HDAC6 1398/4885HPGD 3791/4885
US-20090203692-A1 NOVEL CHEMICAL COMPOUNDS HIPK3, HIPK1, HIPK4 HDAC1 1549/4885HDAC6 194/4885HPGD 3497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.